ContextThroughout its course, there has been talk of ending the AIDS epidemic. Initially aspirational in nature, this discourse has now taken the form of an explicit UNAIDS proposal to maximize the number of infected people who are tested and receive antiretroviral treatment (ART). If the milestones are met by 2020, the proposal states, an end to the AIDS pandemic could be achieved by 2030. This article uses a historical approach to explore whether this strategy to end the epidemic is feasible. MethodsIn this article, I identify historical analogues of today's UNAIDS plan for STDs. I then examine features of today's HIV campaign and compare them with elements of syphilis eradication campaigns that carried out widespread testing and treatment between the 1930s and 1960s. FindingsTwentieth-century syphilis campaigns failed because they did not issue specific proposals that would enable them to achieve their eradication goal. They could not change the features of the disease that impeded their test-and-treat strategy: the moral framing (stigma deters people from testing), biologic factors (asymptomatic periods of contagiousness), and epidemiologic issues (difficulty tracking contacts occurring in private settings). Furthermore, they could not ensure sustainable funding, rectify social problems that create vulnerable environments, or issue educational messages to curb unsafe behaviors. Today's UNAIDS campaign offers no new provisions to address those factors that led to the failure of earlier syphilis campaigns. ConclusionsThe distinctive array of socioeconomic, biologic, and epidemiologic factors that characterize STDs like syphilis also apply to AIDS and weaken the assumption that the AIDS epidemic can be ended by implementing today's UNAIDS plan. The discourse of ending the AIDS epidemic may be a carryover from the successful elimination, before the appearance of AIDS, of smallpoxa disease that is not comparable to AIDS owing to different biologic qualities, social concerns, epidemiologic behaviors, and the possession of an effective vaccine. Future AIDS control campaigns should therefore concentrate on maximizing ART distribution and not targeting the end of the epidemic.